MedTechIQ_3Helix InSight Engine-Beta
Preview
Open in TheBrain
Triple Helix Discovery Engine
Funding Opportunities: Pioneers, Architects & Consolidators
*Funding: Surgery_Surgical Technology, Minimally Invasive & Operating Room of the Future (ORF)
*Venture Capital Companies: Life Science, Health IT & Healthcare Investors
Quaker BioVentures
*Portfolio Companies: Quaker BioVentures
Tengion (TNGN)
Organization & Developments: Tengion
Parents
Tengion (TNGN)
Children
2006: Tengion initiated a Phase II clinical trial of its first product, the neo-bladder, at the end of 2006, under an IND accepted by
2011: Tengion gets notice from NASDAQ over low stock price (2011)
Best known for the research of Anthony Atala, its founder, who runs the Wake Forest Institute for Regenerative Medicine in Piedmont Triad Research Park in Winston-Salem
New human tissues and organs (neo-tissues and neo-organs) that are derived from a patient's own cells
Tengion is a leader in the field of regenerative medicine
Tengion's patented technology harnesses the body's ability to regenerate, and it has the potential to allow patients to have fun
Tengion's scientists identify and multiply the patient's own healthy progenitor cells
The surgeon then implants the neo-organ in the patient's body
Then place these cells on a structure that is shaped like the needed organ or tissue (a bioresorbable scaffold).
Jumps
*Key People: Tengion
Finance & Acquisitions: Tengion